Media Coverage

At 5.7 percent Louisiana’s drug test positivity rate is over 1 percent higher than the national average, according to a map produced by Quest Diagnostics' drug testing index.

Quest Diagnostics Inc (NYSE:DGX) institutional sentiment increased to 0.93 in Q2 2018. Its up 0.13, from 0.8 in 2018Q1. The ratio has increased, as 217 funds opened new and increased equity positions, while 234 cut down and sold their stakes in Quest Diagnostics Inc. The funds in our partner’s database reported: 110.90 million shares, down from 111.81 million shares in 2018Q1. Also, the number of funds holding Quest Diagnostics Inc in their top 10 equity positions increased from 0 to 3 for an increase of 3. Sold All: 30 Reduced: 204 Increased: 145 New Position: 72.

Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4. Their findings provide new insights into the progression of the disease from precursor conditions and suggest approaches for novel treatments. Testing will be performed at each participant's local Quest Diagnostics laboratory. To sign up for the study, please visit http://www.promisestudy.org.

Aetna, a CVS Health business, and Ascension have joined the pilot project applying blockchain technology to improve data quality and reduce administrative costs associated with changes to health care provider demographic data. Humana, MultiPlan, Quest Diagnostics and UnitedHealth Group’s (NYSE: UNH) Optum and UnitedHealthcare announced the launch of the Synaptic Health Alliance pilot project in April.

Quest Diagnostics made it official: It is coming to the city and bringing 1,100 jobs. The company told officials it hopes to break ground for the 250,000-square-foot facility and accompanying five to seven-story parking garage this spring, officials said.

Quest Diagnostics Inc. (Quest), an American diagnostic information service provider, has reportedly announced that it has inked an agreement to acquire the laboratory services business unit belonging to Boyce and Bynum Pathology Laboratories (BBPL), a clinical & diagnostic laboratory service provider.

Parts of Boyce and Bynum Pathology Labs are set to be acquired by Quest Diagnostics. Quest announced they recently signed an agreement to acquire the assets of Boyce and Bynum's clinical laboratory services.

Quest Diagnostics announced today that it will build a 250,000-square-foot flagship laboratory in Clifton, New Jersey. The new laboratory will become the largest of the more than 20 major laboratory facilities in the Quest network and will employ more than 1,100 people. It is expected to be operational in early 2021.

The questions sound familiar: “Describe a time when you went above and beyond;” “Tell me about a time when you had to deliver bad news to a customer.” But in this telephone job interview, there is a twist: No human is on the other end of the line. Major companies such as laboratory-test provider Quest Diagnostics Inc., hospital operator HCA Healthcare Inc. and insurer Allstate Insurance Co. use such interviews for some hiring, as do retailers, restaurant chains and law firms.

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories (BBPL), a leading provider of diagnostic and clinical laboratory services in the Midwest.